CA2138997A1 - Vaccine composition containing adjuvants - Google Patents

Vaccine composition containing adjuvants

Info

Publication number
CA2138997A1
CA2138997A1 CA002138997A CA2138997A CA2138997A1 CA 2138997 A1 CA2138997 A1 CA 2138997A1 CA 002138997 A CA002138997 A CA 002138997A CA 2138997 A CA2138997 A CA 2138997A CA 2138997 A1 CA2138997 A1 CA 2138997A1
Authority
CA
Canada
Prior art keywords
composition containing
vaccine composition
containing adjuvants
adjuvants
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002138997A
Other languages
French (fr)
Other versions
CA2138997C (en
Inventor
Jean-Paul Prieels
Nathalie Marie-Josephe Claude Garcon-Johnson
Moncef Slaoui
Pietro Pala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
Jean-Paul Prieels
Nathalie Marie-Josephe Claude Garcon-Johnson
Moncef Slaoui
Pietro Pala
Smithkline Beecham Biologicals S.A.
Smithkline Beecham Biologicals (S.A.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9213559A external-priority patent/GB9213559D0/en
Priority claimed from GB929226283A external-priority patent/GB9226283D0/en
Priority claimed from GB939304056A external-priority patent/GB9304056D0/en
Application filed by Jean-Paul Prieels, Nathalie Marie-Josephe Claude Garcon-Johnson, Moncef Slaoui, Pietro Pala, Smithkline Beecham Biologicals S.A., Smithkline Beecham Biologicals (S.A.) filed Critical Jean-Paul Prieels
Publication of CA2138997A1 publication Critical patent/CA2138997A1/en
Application granted granted Critical
Publication of CA2138997C publication Critical patent/CA2138997C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides vaccine compositions comprising 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccines compositions are potent inducers of CTL and .gamma. IFN responses.
CA002138997A 1992-06-25 1993-06-15 Vaccine composition containing adjuvants Expired - Lifetime CA2138997C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9213559A GB9213559D0 (en) 1992-06-25 1992-06-25 Vaccines
GB9213559.9 1992-06-25
GB9226283.1 1992-12-17
GB929226283A GB9226283D0 (en) 1992-12-17 1992-12-17 Vaccines
GB939304056A GB9304056D0 (en) 1993-03-01 1993-03-01 Vaccines
GB9304056.6 1993-03-01
PCT/EP1993/001524 WO1994000153A1 (en) 1992-06-25 1993-06-15 Vaccine composition containing adjuvants

Publications (2)

Publication Number Publication Date
CA2138997A1 true CA2138997A1 (en) 1994-01-06
CA2138997C CA2138997C (en) 2003-06-03

Family

ID=27266263

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002138997A Expired - Lifetime CA2138997C (en) 1992-06-25 1993-06-15 Vaccine composition containing adjuvants

Country Status (31)

Country Link
US (2) US5750110A (en)
EP (2) EP0761231B1 (en)
JP (1) JP3755890B2 (en)
KR (1) KR100278157B1 (en)
CN (1) CN1122530C (en)
AP (1) AP408A (en)
AT (2) ATE156710T1 (en)
AU (1) AU661404B2 (en)
CA (1) CA2138997C (en)
CZ (1) CZ282235B6 (en)
DE (2) DE69313134T2 (en)
DK (2) DK0671948T3 (en)
ES (2) ES2143716T3 (en)
FI (1) FI109767B (en)
GR (2) GR3025184T3 (en)
HK (2) HK1022074A1 (en)
HU (1) HU219808B (en)
IL (1) IL106109A (en)
MA (1) MA22911A1 (en)
MX (1) MX9303773A (en)
MY (1) MY109278A (en)
NO (1) NO317546B1 (en)
NZ (1) NZ253137A (en)
PL (1) PL170980B1 (en)
PT (1) PT761231E (en)
RU (1) RU2118164C1 (en)
SG (2) SG90042A1 (en)
SI (1) SI9300335B (en)
SK (1) SK279188B6 (en)
UA (1) UA40597C2 (en)
WO (1) WO1994000153A1 (en)

Families Citing this family (460)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
EP0761231B1 (en) * 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
AU6141094A (en) * 1993-02-19 1994-09-14 Smithkline Beecham Biologicals (Sa) Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
US5773011A (en) * 1993-09-27 1998-06-30 Gerbu Biotechnik Gmbh Method of preparing a synergistic immunological adjuvant formulation
US6083513A (en) * 1993-11-16 2000-07-04 Gerbu Biotechnik Gmbh Method for increasing the yield of antibodies in the techniques of immunology
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM446594A0 (en) * 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines
US20010053365A1 (en) * 1995-04-25 2001-12-20 Smithkline Beecham Biologicals S.A. Vaccines
UA56132C2 (en) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US6846489B1 (en) * 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
EP0909323B1 (en) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Helicobacter pylori bacterioferritin
US7112331B2 (en) 1996-02-09 2006-09-26 Smithkline Beecham Biologicals, S.A. Vaccines against varicella zoster virus gene 63 product
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
JP4583511B2 (en) * 1997-05-20 2010-11-17 ガレニカ ファーマシューティカルズ， インコーポレイテッド Triterpene saponin analogs with adjuvant and immunostimulatory activity
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
KR100633212B1 (en) 1998-02-05 2006-10-11 글락소스미스클라인 바이오로지칼즈 에스.에이. Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP4227302B2 (en) 1998-04-07 2009-02-18 コリクサ コーポレイション MYCOBACTERIUMUMBERBERCULOSIS antigen fusion protein and use thereof
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
BR9910005A (en) * 1998-04-29 2001-01-16 American Cyanamid Co Vaccine composition, processes for immunization against neisseria gonorrhoeae and to prepare a vaccine composition, isolated and purified DNA sequence, plasmid, host cell, process for producing a chimeric recombinant pilin protein from neisseria gonorrhoeae and neisseria meningitidis, chimeric recombinant protein isolated and purified from neisseria gonorhoeae and neisseria meningitidis, and, process for immunization against neisseria muningitidis
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
WO2000008051A2 (en) * 1998-08-07 2000-02-17 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
US6262029B1 (en) 1998-08-14 2001-07-17 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
PL201482B1 (en) * 1998-10-16 2009-04-30 Smithkline Beecham Biolog Adjuvant systems and vaccines
GB9826886D0 (en) * 1998-12-07 1999-01-27 Smithkline Beecham Biolog Novel compounds
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
BR9916020A (en) 1998-12-08 2002-01-22 Corixa Corp Compounds and methods for the treatment and diagnosis of chlamydia infection
ES2374055T3 (en) 1998-12-08 2012-02-13 Glaxosmithkline Biologicals S.A. NEW COMPOUNDS DERIVED FROM NEISSERIA MENINGITIDIS.
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7666988B1 (en) 1999-03-12 2010-02-23 Glaxosmithkline Biologicals S.A. BASB082 Polypeptides
SI1163000T1 (en) 1999-03-19 2008-06-30 Glaxosmithkline Biolog Sa Vaccine against antigens from bacteriae
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
JP2002543769A (en) 1999-04-02 2002-12-24 コリクサ コーポレイション Compounds and methods for treatment and diagnosis of lung cancer
PL203951B1 (en) 1999-04-19 2009-11-30 Smithkline Beecham Biolog Vaccines
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9919468D0 (en) 1999-08-17 1999-10-20 Smithkline Beecham Biolog Vaccine
EP1808180A3 (en) 1999-10-22 2010-12-22 Sanofi Pasteur Limited Modified GP 100 and uses thereof
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
MXPA02007413A (en) * 2000-01-31 2004-07-30 Smithkline Beecham Biolog Novel use.
DK1265915T3 (en) 2000-02-23 2011-02-14 Glaxosmithkline Biolog Sa New connections
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
ES2303525T3 (en) 2000-04-21 2008-08-16 Corixa Corporation COMPOUNDS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF INFECTION BY CHLAMYDIA.
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
AU2001258102B2 (en) 2000-05-10 2007-03-01 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
ES2374620T3 (en) 2000-06-20 2012-02-20 Corixa Corporation ANTIGEN MTB32A OF MYCOBACTERIUM TUBERCULOSIS WITH THE ACTIVE ACTIVE SITE AND FUSION PROTEINS OF THEMSELVES.
EP1961819A3 (en) 2000-06-28 2008-11-12 Corixa Corporation Composition and methods for the therapy and diagnosis of lung cancer
US20030180316A1 (en) 2000-06-29 2003-09-25 Dominique Boutriau Multivalent vaccine composition
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
UA79735C2 (en) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Purification of hbv antigens for use in vaccines
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
KR100831139B1 (en) 2000-10-18 2008-05-20 글락소스미스클라인 바이오로지칼즈 에스.에이. Vaccines
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
CA2425303A1 (en) 2000-10-27 2002-05-02 John Telford Nucleic acids and proteins from streptococcus groups a & b
US6892140B1 (en) * 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
CA2430379A1 (en) 2000-12-07 2002-06-13 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP2269639B1 (en) 2001-02-23 2018-11-28 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US20020193295A1 (en) * 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
EP1515982A4 (en) 2001-05-09 2005-10-26 Corixa Corp Compositions and methods for the therapy and diagnosis of prostate cancer
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
US20030108565A1 (en) 2001-07-10 2003-06-12 Johnson Mark E. Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
GB0118367D0 (en) 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
ES2405405T3 (en) 2001-12-17 2013-05-31 Corixa Corporation Compositions and procedures for the therapy and diagnosis of inflammatory bowel disease
US7030094B2 (en) * 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PL209696B1 (en) 2002-04-19 2011-10-31 Univ Toronto Immunological methods and compositions for the treatment of alzheimer's disease
CA2489292A1 (en) 2002-06-13 2003-12-24 Chiron Corporation Vectors for expression of hml-2 polypeptides
EP2316479B8 (en) * 2002-07-18 2015-03-18 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
WO2004014419A1 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
DK2351579T3 (en) 2002-10-11 2017-01-09 Novartis Vaccines And Diagnostics S R L Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages.
PL376792A1 (en) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
EP2279746B1 (en) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
PT1581812E (en) 2003-01-06 2008-09-22 Wyeth Corp Compositions and methods for diagnosing and treating colon cancers
EP2289546A3 (en) 2003-01-30 2011-03-30 Novartis Vaccines and Diagnostics S.r.l. Injectable vaccines against multiple meningococcal serogroups
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
WO2005020964A1 (en) 2003-06-02 2005-03-10 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
PL2272532T3 (en) 2003-09-02 2016-07-29 Glaxosmithkline Biologicals Sa Rotavirus vaccine
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1670506B1 (en) 2003-10-02 2012-11-21 Novartis AG Liquid vaccines for multiple meningococcal serogroups
DE602004028262D1 (en) 2003-10-02 2010-09-02 Glaxosmithkline Biolog Sa B. PERTUSSIS ANTIGENE AND ITS USE IN VACCINATION
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
AU2004308964B2 (en) 2003-12-23 2010-09-16 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
AU2005213457A1 (en) 2004-02-05 2005-08-25 The Ohio State University Research Foundation Chimeric VEGF peptides
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
BRPI0510315A (en) 2004-04-30 2007-10-16 Chiron Srl integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
US20090104226A1 (en) 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
AU2005285513B2 (en) 2004-05-25 2011-02-24 Oregon Health And Science University SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
DE602005025342D1 (en) 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa VACCINE COMPOSITIONS WITH VIRUSOMES AND A SAPONIN ADJUVANS
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
ES2540770T3 (en) 2004-09-22 2015-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition for use in staphylococcal vaccination
EP1797173B1 (en) 2004-10-08 2014-05-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Modulation of replicative fitness by using less frequently used synonymous codons
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
PE20061329A1 (en) 2004-12-15 2006-12-08 Neuralab Ltd HUMANIZED AB ANTIBODIES TO IMPROVE COGNITION
EP2433647A3 (en) 2005-01-27 2012-06-06 Children's Hospital & Research Center at Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
WO2006089264A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
JP2008530245A (en) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Antigens from uropathogenic strains
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
WO2006104890A2 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
ES2524570T3 (en) 2005-04-29 2014-12-10 Glaxosmithkline Biologicals S.A. Procedure for prevention or treatment of infection with M. tuberculosis
AU2006261342B2 (en) 2005-06-15 2012-02-02 The Ohio State University Research Foundation Her-2 peptides
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
EP2305701A1 (en) 2005-07-01 2011-04-06 Forsyth Dental Infirmary for Children Tuberculosis antigen detection assays and vaccines
EP1945247A1 (en) 2005-10-18 2008-07-23 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628424A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted influenza vaccines including cytokine-inducing agents
HUE051122T2 (en) 2005-11-04 2021-03-01 Seqirus Uk Ltd Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
BRPI0618254A2 (en) * 2005-11-04 2011-08-23 Novartis Vaccines & Diagnostic free aqueous phase surfactant emulsions to provide adjuvant to split influenza vaccines
ES2514316T3 (en) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CN101378778B (en) 2005-12-22 2013-02-06 葛兰素史密丝克莱恩生物有限公司 Vaccine comprising streptococcus pneumoniae capsular polyaccharide conjugates
US7848801B2 (en) 2005-12-30 2010-12-07 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
EP1981905B1 (en) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
UA92782C2 (en) 2006-01-17 2010-12-10 Арне Форсгрен Novel surface exposed haemophilus influenzae protein (protein e - pe)
PT2478916T (en) 2006-01-27 2020-07-03 Seqirus Uk Ltd Influenza vaccines containing hemagglutinin and matrix proteins
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2382987A1 (en) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Storage of influenza vaccines without refrigeration
KR101149687B1 (en) 2006-03-30 2012-05-25 엠브렉스, 인코포레이티드 Methods and compositions for vaccination of poultry
EA015833B1 (en) 2006-03-30 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Immunogenic composition
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20100021424A1 (en) 2006-06-02 2010-01-28 Vincent Brichard Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
EP2032161B1 (en) 2006-06-12 2012-07-11 GlaxoSmithKline Biologicals S.A. L3v los vaccines
BRPI0715581A2 (en) 2006-07-18 2013-04-24 Glaxosmithkline Biolog Sa immunogenic hybrid fusion protein, composition, use of a protein or particle, method for treating a patient susceptible to plasmid infection, nucleotide sequence, host, and process for protein production
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
EP2054081A4 (en) * 2006-08-31 2010-07-21 Baylor Res Inst Jc virus vaccine
NZ575273A (en) 2006-09-07 2012-02-24 Glaxosmithkline Biolog Sa Method for making combination vaccine comprising inactivated poliovirus type 1, diptheria toxoid and tetanus toxoid
ES2536401T3 (en) 2006-09-11 2015-05-25 Novartis Ag Making vaccines against influenza viruses without using eggs
EP2486938B1 (en) 2006-09-26 2018-05-09 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20110045022A1 (en) 2006-12-06 2011-02-24 Theodore Tsai Vaccines including antigen from four strains of influenza virus
MX2009009342A (en) 2007-03-02 2009-09-11 Glaxosmithkline Biolog Sa Novel method and compositions.
CN101687027B (en) 2007-04-04 2015-01-28 传染性疾病研究院 Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PE20090212A1 (en) 2007-05-02 2009-03-30 Glaxosmithkline Biolog Sa VACCINE KIT FOR PRIMARY IMMUNIZATION
JP2010531330A (en) 2007-06-26 2010-09-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Vaccine containing Streptococcus pneumoniae capsular polysaccharide conjugate
PT2185191E (en) 2007-06-27 2012-11-27 Novartis Ag Low-additive influenza vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
ES2498040T3 (en) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanized anti-beta antibodies
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
AU2008281384C1 (en) * 2007-08-02 2012-08-16 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
CN102027003A (en) 2007-08-03 2011-04-20 哈佛大学校长及研究员协会 Chlamydia antigens
AR067905A1 (en) 2007-08-13 2009-10-28 Glaxosmithkline Biolog Sa VACCINES
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
EP2201131B8 (en) 2007-09-17 2014-12-10 MDxHealth SA Improved methylation detection
EP2045263A1 (en) 2007-10-02 2009-04-08 Universite Libre De Bruxelles Identification and molecular characterisation of salivary metalloproteases expressed in the tick salivary glands
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CA2744739A1 (en) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
EP3118213A1 (en) 2007-12-19 2017-01-18 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
NZ586430A (en) 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)
CA2710600C (en) * 2007-12-24 2017-06-06 Id Biomedical Corporation Of Quebec Recombinant rsv antigens
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
EP2265640B1 (en) 2008-03-10 2015-11-04 Children's Hospital & Research Center at Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
WO2009127666A2 (en) * 2008-04-15 2009-10-22 Glaxosmithkline Biologicals S.A. Method and compositions
EP3329931B1 (en) 2008-04-18 2022-06-08 The General Hospital Corporation Immunotherapies employing self-assembling vaccines
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
CA2731194A1 (en) * 2008-07-18 2010-01-21 Id Biomedical Corporation Of Quebec Chimeric respiratory syncytial virus polypeptide antigens
CA2731547C (en) 2008-07-25 2019-04-30 Glaxo Group Limited The tuberculosis rv2386c protein, compositions and uses thereof
UA107180C2 (en) 2008-07-25 2014-12-10 Глаксосмітклайн Байолоджікалз С.А. Rv1753c tuberculosis protein, composition containing it and administration
KR101707569B1 (en) 2008-08-01 2017-02-16 감마 백신즈 피티와이 리미티드 Influenza vaccines
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
EP2349209A2 (en) 2008-09-26 2011-08-03 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2743904A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
BRPI0922132A2 (en) 2008-12-03 2018-10-23 Protea Vaccine Tech Ltd glutamyl trna synthetase fragments (gts).
EP2376108B1 (en) 2008-12-09 2017-02-22 Pfizer Vaccines LLC IgE CH3 PEPTIDE VACCINE
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
MX2011007456A (en) 2009-01-12 2011-08-03 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria.
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
CA2751379C (en) 2009-02-10 2018-06-12 Novartis Ag Influenza vaccines with reduced amounts of squalene
AU2010220103A1 (en) 2009-03-06 2011-09-22 Novartis Ag Chlamydia antigens
CN102575284A (en) 2009-03-17 2012-07-11 MDx健康公司 Improved detection of gene expression
US9044447B2 (en) 2009-04-03 2015-06-02 University Of Washington Antigenic peptide of HSV-2 and methods for using same
SG175092A1 (en) 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
ES2552153T3 (en) 2009-04-30 2015-11-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
TWI494125B (en) 2009-06-05 2015-08-01 Infectious Disease Res Inst Synthetic glucopyranosyl lipid adjuvants
EP2442826B1 (en) 2009-06-15 2015-07-08 National University of Singapore Influenza vaccine, composition, and methods of use
US20100316673A1 (en) 2009-06-16 2010-12-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
SG176807A1 (en) 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
PE20121541A1 (en) 2009-06-24 2012-12-21 Glaxosmithkline Biolog Sa RECOMBINANT RESPIRATORY SYNCIZAL VIRUS ANTIGENS
ES2662716T3 (en) 2009-07-07 2018-04-09 Glaxosmithkline Biologicals Sa Preserved immunogens of Escherichia coli
SG178026A1 (en) 2009-07-15 2012-03-29 Novartis Ag Rsv f protein compositions and methods for making same
ES2526996T3 (en) 2009-07-16 2015-01-19 Novartis Ag Detoxified immunogens from Escherichia coli
PE20120817A1 (en) 2009-07-30 2012-07-07 Pfizer Vaccines Llc ANTIGENIC TAU PEPTIDES AND USES OF THEM
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
KR101873179B1 (en) * 2009-08-26 2018-06-29 셀렉타 바이오사이언시즈, 인크. Compositions that induce t cell help
NZ598458A (en) 2009-08-27 2014-03-28 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
CA2846746A1 (en) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
CN102695523A (en) 2009-09-10 2012-09-26 诺华有限公司 Combination vaccines against respiratory tract diseases
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
CN102724988B (en) 2009-09-30 2014-09-10 诺华股份有限公司 Expression of meningococcal fHBP polypeptides
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
JP5960055B2 (en) 2009-10-27 2016-08-02 ノバルティス アーゲー Modified meningococcal fHBP polypeptide
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
KR20120120185A (en) 2009-12-22 2012-11-01 셀덱스 쎄라퓨틱스, 인크. Vaccine compositions
EP2519265B1 (en) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Polysaccharide immunogens conjugated to e. coli carrier proteins
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
US20130004530A1 (en) 2010-03-10 2013-01-03 Jan Poolman Vaccine composition
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
MX2012011189A (en) 2010-03-26 2013-02-07 Glaxosmithkline Biolog Sa Hiv vaccine.
EP2552942B1 (en) 2010-03-30 2017-12-27 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2556151A1 (en) 2010-04-07 2013-02-13 Novartis AG Method for generating a parvovirus b19 virus-like particle
MX2012013713A (en) 2010-05-26 2013-01-28 Selecta Biosciences Inc Nanocarrier compositions with uncoupled adjuvant.
DK2575870T3 (en) 2010-06-04 2017-02-13 Wyeth Llc vaccine Formulations
EP2576613A1 (en) 2010-06-07 2013-04-10 Pfizer Inc. Her-2 peptides and vaccines
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP3153578A1 (en) 2010-07-06 2017-04-12 Novartis Ag Norovirus derived immunogenic compositions and methods
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
AU2011310838B2 (en) 2010-09-27 2015-11-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
US20130280322A1 (en) 2010-09-27 2013-10-24 Glaxosmithkline Biologicals S.A. Vaccine
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
WO2012057904A1 (en) 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
BR112013011420A2 (en) 2010-11-08 2016-08-02 Infectious Disease Res Inst vaccines comprising nonspecific nucleoside hydrolase polypeptides and sterol 24-c-methyl transferase (smt) for the treatment and diagnosis of leishmaniasis
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2646459B1 (en) 2010-12-02 2020-01-08 Bionor Immuno AS Peptide scaffold design
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
WO2012092934A1 (en) 2011-01-06 2012-07-12 Bionor Immuno As Monomeric and multimeric immunogenic peptides
AU2012211278B2 (en) 2011-01-26 2016-11-10 Glaxosmithkline Biologicals Sa RSV immunization regimen
EP2667891B1 (en) 2011-01-27 2021-10-06 Gamma Vaccines Pty Limited Combination vaccines
US9303070B2 (en) 2011-02-22 2016-04-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
ES2716010T3 (en) 2011-03-29 2019-06-07 Uab Research Foundation Methods and compositions for cytomegalovirus IL-10 protein
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
JP6054942B2 (en) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション Immunogenic compositions and methods of using the compositions to elicit humoral and cellular immune responses
TW201302779A (en) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa Fusion proteins & combination vaccines
LT2707385T (en) 2011-05-13 2017-12-11 Glaxosmithkline Biologicals Sa Pre-fusion rsv f antigens
US20130156803A1 (en) 2011-06-04 2013-06-20 Rochester General Hospital Research Institute Compositions and methods related to p6
EP2691530B1 (en) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2012177595A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
ES2687129T3 (en) 2011-07-25 2018-10-23 Glaxosmithkline Biologicals Sa Compositions and methods to evaluate the functional immunogenicity of parvovirus vaccines
EA201490381A1 (en) 2011-07-29 2014-06-30 Селекта Байосайенсиз, Инк. SYNTHETIC NANOSEAGES WHICH STIMULATE THE FORMATION OF HUMORAL IMMUNE RESPONSE AND IMMUNE RESPONSE MEDIATED BY CYTOTOXIC T-LYMPHOCYTES (CTL)
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
GB201114919D0 (en) 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
AU2012308149A1 (en) 2011-09-12 2014-03-27 Sheena Mary Geraldine MCCORMACK Methods and compositions for raising an immune response to HIV
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9511130B2 (en) 2011-09-14 2016-12-06 Glaxosmithkline Biologicals Sa Escherichia coli vaccine combination
CN103917245B (en) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 Method for preparing glycoprotein glycoconjugate
EP3617227A3 (en) 2011-09-16 2020-06-03 UCB Biopharma SRL Neutralising antibodies to the major exotoxin tcda of clostridium difficile
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
US9694063B2 (en) 2011-12-08 2017-07-04 Glaxosmithkline Biologicals Sa Clostridium difficile toxin-based vaccine
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
US11510875B2 (en) 2012-02-07 2022-11-29 Access To Advanced Health Institute Adjuvant formulations comprising TLR4 agonists and methods of using the same
US20150273042A1 (en) 2012-02-24 2015-10-01 Novartis Ag Pilus proteins and compositions
US20130236484A1 (en) 2012-03-08 2013-09-12 Detectogen Inc. Leishmaniasis antigen detection assays and vaccines
ES2702278T3 (en) 2012-04-01 2019-02-28 Technion Res & Dev Foundation Extracellular matrix metalloproteinase (emmprin) inducer peptides and binding antibodies
CN104428312A (en) 2012-04-02 2015-03-18 北卡罗来纳-查佩尔山大学 Methods and compositions for dengue virus epitopes
ES2837825T3 (en) 2012-04-26 2021-07-01 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
PE20142406A1 (en) 2012-05-04 2015-01-23 Pfizer ANTIGENS ASSOCIATED WITH PROSTATE AND VACCINE-BASED IMMUNOTHERAPY REGIMES
BR112014028476A2 (en) 2012-05-16 2017-08-01 Immune Design Corp immunogenic fragment of a polypeptide, isolated polynucleotide, immunogenic pharmaceutical composition, methods for treating an infection, for generating an immune response in a subject, and for immunizing a subject
CN104736180A (en) 2012-05-22 2015-06-24 诺华股份有限公司 Meningococcus serogroup X conjugate
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
US10501499B2 (en) 2012-06-06 2019-12-10 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
BR112015002483A2 (en) 2012-08-03 2017-11-07 Infectious Disease Res Inst compositions and methods for treating an active infection with mycobacterium tuberculosis
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
US10232035B2 (en) 2012-09-14 2019-03-19 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes virus and use thereof in vaccines
RU2662970C2 (en) 2012-09-18 2018-07-31 Новартис Аг Outer membrane vesicles
MX2015004171A (en) 2012-10-02 2015-10-22 Glaxosmithkline Biolog Sa Nonlinear saccharide conjugates.
AU2013326503B2 (en) 2012-10-03 2018-04-19 Glaxosmithkline Biologicals Sa Immunogenic composition
US9982034B2 (en) 2012-10-24 2018-05-29 Platelet Targeted Therapeutics, Llc Platelet targeted treatment
ES2656510T3 (en) 2012-11-30 2018-02-27 Glaxosmithkline Biologicals S.A. Pseudomonas antigens and antigen combination
ES2939307T3 (en) 2012-12-05 2023-04-20 Glaxosmithkline Biologicals Sa immunogenic composition
BR112015024860B1 (en) 2013-03-28 2023-11-07 Access To Advanced Health Institute FUSION POLYPEPTIDE, ISOLATED POLYNUCLEOTIDE, COMPOSITION COMPRISING SAID POLYPEPTIDE, USE OF SAID COMPOSITION TO STIMULATE AN IMMUNE RESPONSE AGAINST LEISHMANIA AND IN VITRO METHOD AND DIAGNOSTIC KIT FOR DETECTING LEISHMANIA INFECTION IN A BIOLOGICAL SPECIMEN
EA032326B1 (en) 2013-04-18 2019-05-31 Иммьюн Дизайн Корп. Gla monotherapy for use in cancer treatment
WO2015132619A1 (en) 2013-05-15 2015-09-11 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
CN110734500A (en) 2013-06-26 2020-01-31 北卡罗来纳-查佩尔山大学 Methods and compositions for dengue virus vaccines
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3063171B1 (en) 2013-11-01 2019-07-24 University Of Oslo Albumin variants and uses thereof
US9993541B2 (en) 2013-11-13 2018-06-12 University Of Oslo Outer membrane vesicles and uses thereof
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
WO2015103104A1 (en) 2014-01-06 2015-07-09 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated salmonella enterica
AU2015208821B2 (en) 2014-01-21 2017-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
TW201620927A (en) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 USPA2 protein constructs and uses thereof
WO2015148648A1 (en) * 2014-03-25 2015-10-01 The Government Of The United States Of America As Represented By The Secretary Of The Army Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
EP3160500B1 (en) 2014-06-25 2019-08-21 GlaxoSmithKline Biologicals S.A. Clostridium difficile immunogenic composition
TW201623329A (en) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 Vaccines and monoclonal antibodies targeting truncated variants of osteopontin and uses thereof
WO2016011386A1 (en) 2014-07-18 2016-01-21 University Of Washington Cancer vaccine compositions and methods of use thereof
WO2016012385A1 (en) 2014-07-21 2016-01-28 Sanofi Pasteur Vaccine composition comprising ipv and cyclodextrins
JP6796057B2 (en) 2014-07-23 2020-12-02 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド H factor binding protein mutant and its usage
EP3204039B1 (en) 2014-10-10 2022-06-08 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
WO2016070178A1 (en) 2014-11-02 2016-05-06 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
MX2017007652A (en) 2014-12-10 2017-10-11 Glaxosmithkline Biologicals Sa Method of treatment.
DK3244917T3 (en) 2015-01-15 2023-05-22 Pfizer Immunogenic compositions for use in pneumococcal vaccines
WO2016134300A1 (en) 2015-02-20 2016-08-25 Board Of Regents, The University Of Texas System Methods and compositions for attenuated chlamydia as vaccine and vector
CN107249629A (en) * 2015-02-26 2017-10-13 生控基因疫苗股份有限公司 Comprising immunogenic protein and combination adjuvant and to induce the vaccine combination that T cells with antigenic specificity reacts
CN107530416A (en) 2015-03-05 2018-01-02 西北大学 Virus that non-nerve infects and application thereof
EP3270897A4 (en) 2015-03-20 2018-12-05 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10821168B2 (en) 2015-03-26 2020-11-03 Gpn Vaccines Pty Ltd Streptococcal vaccine
WO2016191553A1 (en) 2015-05-26 2016-12-01 Ohio State Innovation Foundation Nanoparticle based vaccine strategy against swine influenza virus
AU2016271857B2 (en) 2015-06-03 2020-05-28 Affiris Ag IL-23-P19 vaccines
AU2016281904B2 (en) 2015-06-26 2022-08-11 Seqirus UK Limited Antigenically matched influenza vaccines
CN107849119A (en) 2015-07-07 2018-03-27 阿费里斯股份公司 For the vaccine for the disease for treating and preventing IgE mediations
NZ739007A (en) 2015-07-21 2022-08-26 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2017062246A1 (en) 2015-10-05 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rota virus g9p[6] strain and use as a vaccine
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
BR112018013967A2 (en) 2016-01-19 2019-02-05 Pfizer cancer vaccines
WO2017137085A1 (en) 2016-02-11 2017-08-17 Sanofi Pasteur Meningitidis vaccines comprising subtilinases
MX2018010961A (en) 2016-03-10 2019-03-28 Aperisys Inc Antigen-binding fusion proteins with modified hsp70 domains.
KR20180127320A (en) 2016-03-14 2018-11-28 유니버시티에트 이 오슬로 A modified immunoglobulin with altered FcRn binding
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
CN109310773B (en) 2016-05-16 2022-04-26 传染病研究所 Formulations containing TLR agonists and methods of use
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
CA3024313A1 (en) 2016-05-21 2017-11-30 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
AU2017273650B2 (en) 2016-06-01 2022-08-18 Access To Advanced Health Institute Nanoalum particles containing a sizing agent
EP3471761A2 (en) 2016-06-21 2019-04-24 University Of Oslo Hla binding vaccine moieties and uses thereof
WO2018037045A1 (en) 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
WO2018053294A1 (en) 2016-09-16 2018-03-22 Infectious Disease Research Institute Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
BE1024774B1 (en) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa COMPOSITIONS AND METHODS OF TREATMENT
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
ES2911490T3 (en) 2017-01-20 2022-05-19 Pfizer Immunogenic compositions for use in pneumococcal vaccines
JP2020515587A (en) 2017-03-31 2020-05-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Immunogenic compositions, uses and methods of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
US11583578B2 (en) 2017-04-28 2023-02-21 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Plasmodium falciparum recombinanr xiexumapoeozoite protein compositions and method for vaccine delivery
CN110996994A (en) 2017-08-14 2020-04-10 葛兰素史密丝克莱恩生物有限公司 Method for enhancing immune response
US11123415B2 (en) 2017-08-16 2021-09-21 Ohio State Innovation Foundation Nanoparticle compositions for Salmonella vaccines
US20220118076A1 (en) 2017-09-07 2022-04-21 University Of Oslo Vaccine molecules
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
JP7339942B2 (en) 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート Liposomal formulation containing saponin and method of use
BR112020004747A2 (en) 2017-09-13 2020-09-24 Sanofi Pasteur immunogenic composition of human cytomegalovirus
US11566050B2 (en) 2017-10-18 2023-01-31 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus vaccines and diagnostics
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
WO2019175147A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against intra-abdominal infections
CN112638936A (en) 2018-06-12 2021-04-09 葛兰素史密丝克莱恩生物有限公司 Adenovirus polynucleotides and polypeptides
CA3107077A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
WO2020039033A1 (en) 2018-08-23 2020-02-27 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7320601B2 (en) 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 Broad-spectrum anti-influenza vaccine immunogen and its use
EP3890775A1 (en) 2018-12-06 2021-10-13 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
EP3893926A1 (en) 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
JP7239509B6 (en) 2019-02-22 2023-03-28 ファイザー・インク Method for purifying bacterial polysaccharides
WO2020178359A1 (en) 2019-03-05 2020-09-10 Glaxosmithkline Biologicals Sa Hepatitis b immunisation regimen and compositions
CR20210522A (en) 2019-03-18 2021-12-17 Janssen Pharmaceuticals Inc Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
TWI771663B (en) 2019-03-18 2022-07-21 美商詹森藥物公司 Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3956666A1 (en) 2019-04-18 2022-02-23 GlaxoSmithKline Biologicals S.A. Antigen binding proteins and assays
WO2021023691A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Immunogenic composition
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
BR112022005615A2 (en) 2019-10-02 2022-07-12 Janssen Vaccines & Prevention Bv STAPHYLOCOCCUS PEPTIDES AND METHODS OF USE
WO2021084429A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
US20230045642A1 (en) 2019-12-19 2023-02-09 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
JP2023500749A (en) 2020-01-16 2023-01-10 ヤンセン ファーマシューティカルズ，インコーポレーテッド FimH variants, compositions thereof, and uses thereof
AU2021211012A1 (en) 2020-01-24 2022-08-25 Aim Immunotech Inc. Methods, compositions, and vaccines for treating a virus infection
EP4103587A1 (en) 2020-02-14 2022-12-21 Immunor AS Corona virus vaccine
IL295713A (en) 2020-02-21 2022-10-01 Pfizer Purification of saccharides
PE20230170A1 (en) 2020-02-23 2023-02-01 Pfizer ESCHERICHIA COLI COMPOSITIONS AND THEIR METHODS
WO2022029024A1 (en) 2020-08-03 2022-02-10 Glaxosmithkline Biologicals Sa Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof
JP2023539943A (en) 2020-09-17 2023-09-20 ヤンセン ファーマシューティカルズ，インコーポレーテッド Multivalent vaccine composition and its use
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
EP4234585A1 (en) 2020-10-23 2023-08-30 Jiangsu Provincial Center for Disease Control and Prevention (Public Health Research Institute of Jiangsu Province) Fusion protein and application thereof
PE20231934A1 (en) 2020-10-27 2023-12-01 Pfizer COMPOSITIONS OF ESCHERICHIA COLI AND METHODS THEREOF
JP2022075575A (en) 2020-11-04 2022-05-18 ファイザー・インク Immunogenic compositions for use in pneumococcal vaccines
CA3200968A1 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
JP2024502854A (en) 2021-01-12 2024-01-23 ヤンセン ファーマシューティカルズ，インコーポレーテッド FimH variants, compositions containing them, and uses thereof
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
JP2024507828A (en) 2021-02-19 2024-02-21 サノフィ パスツール インコーポレイテッド Group B meningococcal recombinant vaccine
EP4294433A1 (en) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Immunogenic composition, use and methods
AU2022251305A1 (en) 2021-04-01 2023-09-07 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112023023671A2 (en) 2021-05-28 2024-02-06 Pfizer IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACHARIDE ANTIGENS AND USES THEREOF
WO2023092090A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
NZ209308A (en) 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
FI861417A0 (en) 1985-04-15 1986-04-01 Endotronics Inc HEPATITIS B YTANTIGEN FRAMSTAELLD MED REKOMBINANT-DNA-TEKNIK, VACCIN, DIAGNOSTISKT MEDEL OCH CELLINJER SAMT FOERFARANDEN FOER FRAMSTAELLNING DAERAV.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
ES2056799T3 (en) 1987-07-17 1994-10-16 Rhein Biotech Ges Fur Biotechn CODANT DNA MOLECULES FOR THE FMDH CONTROL AND STRUCTURAL GENE REGIONS FOR A PROTEIN THAT HAS AN FMDH ACTIVITY AND ITS USE.
WO1989011128A1 (en) * 1988-05-03 1989-11-16 Wang Laboratories, Inc. Microprocessor having external control store
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE159031T1 (en) 1989-07-25 1997-10-15 Smithkline Biolog ANTIGENS AND METHODS FOR THE PRODUCTION THEREOF
DE69228698T2 (en) 1991-11-16 1999-09-16 Smithkline Beecham Biolog HYBRID PROTEIN BETWEEN PLASMODIUM AND HBsAG
EP0761231B1 (en) * 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants

Also Published As

Publication number Publication date
EP0761231A1 (en) 1997-03-12
EP0671948B1 (en) 1997-08-13
EP0671948A1 (en) 1995-09-20
IL106109A0 (en) 1993-10-20
NO945003L (en) 1994-12-23
AP9300541A0 (en) 1993-07-31
HK1010097A1 (en) 1999-06-11
CN1122530C (en) 2003-10-01
HU219808B (en) 2001-08-28
SG90042A1 (en) 2002-07-23
NO945003D0 (en) 1994-12-23
ATE156710T1 (en) 1997-08-15
MY109278A (en) 1996-12-31
ES2143716T3 (en) 2000-05-16
PL170980B1 (en) 1997-02-28
FI946064A (en) 1995-02-22
CN1086142A (en) 1994-05-04
DE69327599T2 (en) 2000-08-10
AU661404B2 (en) 1995-07-20
DE69313134T2 (en) 1998-02-26
AP408A (en) 1995-09-27
DK0761231T3 (en) 2000-05-08
RU2118164C1 (en) 1998-08-27
US7147862B1 (en) 2006-12-12
FI109767B (en) 2002-10-15
MA22911A1 (en) 1993-12-31
GR3025184T3 (en) 1998-02-27
PT761231E (en) 2000-06-30
SK279188B6 (en) 1998-07-08
DK0671948T3 (en) 1997-09-01
HU9403778D0 (en) 1995-02-28
HK1022074A1 (en) 2000-07-21
IL106109A (en) 1997-02-18
CZ282235B6 (en) 1997-06-11
SK159294A3 (en) 1995-08-09
WO1994000153A1 (en) 1994-01-06
CZ329694A3 (en) 1995-08-16
UA40597C2 (en) 2001-08-15
JPH07508512A (en) 1995-09-21
DE69327599D1 (en) 2000-02-17
ES2108278T3 (en) 1997-12-16
NZ253137A (en) 1996-08-27
ATE188613T1 (en) 2000-01-15
SI9300335A (en) 1993-12-31
GR3032742T3 (en) 2000-06-30
KR100278157B1 (en) 2001-01-15
SG49909A1 (en) 1998-06-15
RU94046232A (en) 1996-10-10
EP0761231B1 (en) 2000-01-12
SI9300335B (en) 2003-04-30
HUT71208A (en) 1995-11-28
JP3755890B2 (en) 2006-03-15
AU4326393A (en) 1994-01-24
MX9303773A (en) 1994-05-31
KR950702125A (en) 1995-06-19
FI946064A0 (en) 1994-12-23
US5750110A (en) 1998-05-12
DE69313134D1 (en) 1997-09-18
NO317546B1 (en) 2004-11-15
CA2138997C (en) 2003-06-03

Similar Documents

Publication Publication Date Title
CA2138997A1 (en) Vaccine composition containing adjuvants
AU1316495A (en) Vaccines
DK0812593T4 (en) Vaccine preparations containing 3-O-deacylated monophosphoryl lipid-A
IL101290A0 (en) Vaccine formulations
IL105161A0 (en) Vaccine compositions
ZA90474B (en) Vaccine composition
NZ240369A (en) Muramyl dipeptide derivatives and vaccine compositions
AU3956489A (en) Postemergent herbicide compositions containing silicone glycol adjuvants
AU3614493A (en) Non-toxic lipid vaccine formulations
AU2775692A (en) Recombinant influenza virus vaccine compositions
AU1633092A (en) Non-stinging vaccine composition
AU5273890A (en) Preparation of vaccines
AU640364C (en) Vaccine composition
AU4903590A (en) Vaccine composition
IE900354L (en) Vaccine composition

Legal Events

Date Code Title Description
EEER Examination request